ORGOOrganogenesis Holdings Inc.
Pharmaceutical Preparations
- Revenue
- $564M
- 17% YoY
- Operating margin
- 7.9%
- 3076% YoY
- EBITDA
- $60M
- 386% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 0.3×
- $16M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired-28% of net incomeCash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-247% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear7% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $467M | $451M | $433M | $482M | $564M | 17% |
| Operating income | $72M | $22M | $13M | −$1M | $45M | 3584% |
| Net income | $94M | $16M | $5M | $900K | $37M | 4011% |
| Operating cash flow | $62M | $25M | $31M | $14M | −$10M | 173% |
| Capex | $31M | $34M | $24M | $10M | $14M | 41% |
| Stock-based comp | $4M | $7M | $9M | $11M | $13M | 26% |
| Buybacks | — | $0 | $0 | $25M | — |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $7M | $15M | 69 | 120 |
| FY2024 | $7M | $12M | 67 | 114 |
| FY2023 | $6M | $10M | 85 | 115 |
| FY2022 | $6M | −$1M | 56 | 111 |
| FY2021 | $4M | $6M | 192 | 125 |